Petch, Joel, Bressington, Daniel (2021) Aducanumab for Alzheimer’s disease: The never-ending story that nurses should know. Nursing Open, . ISSN 2054-1058. (doi:10.1002/nop2.878) (KAR id:96764)
|
PDF
Publisher pdf
Language: English |
|
|
Download this file (PDF/496kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://onlinelibrary.wiley.com/doi/10.1002/nop2.8... |
|
Abstract
In October 2019, the American pharmaceutical company Biogen stated intention to apply to the US Food and Drug Administration (FDA) for the candidate drug aducanumab to be licenced as a therapeutic agent for the treatment of Alzheimer's disease (AD). If approved, aducanumab would become the first new medication licenced specifically for the treatment of AD in the past decade; and approval in the US may be a precipitant for approval elsewhere.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1002/nop2.878 |
| Uncontrolled keywords: | Aducanumab, Alzheimer's disease, dementia |
| Institutional Unit: | Schools > Kent and Medway Medical School |
| Former Institutional Unit: |
Divisions > Division of Natural Sciences > Kent and Medway Medical School
|
| Depositing User: | Joel Petch |
| Date Deposited: | 07 Sep 2022 07:23 UTC |
| Last Modified: | 22 Jul 2025 09:11 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/96764 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
